Copyright © 2021. Inderes Oyj. All rights reserved.

Q2 operating losses increased y/y, as we anticipated, due to the applied and initiated studies announced in Q2. This was included in the last update's estimates, thus we make no meaningful revisions following the Q2 report, apart from lowering cash spending slightly. The ESMO congress abstract to be released in September, however, could potentially impact our valuation, as it could yield more visibility into the likelihood of CAN04 approval. We raise our DCF-based valuation range to SEK 46-54 (45-52) per share. Marketing material commissioned by Cantargia.

Lähde: Finwire News

Cantargia AB is engaged in the development of products used in the treatment of cancer. It has developed specific antibodies against IL1RAP to treat serious, life-threatening diseases. The company's first product candidate, CAN04, has also been designed to treat different forms of cancer, with the initial focus on the treatment of non-small cell lung cancer and pancreatic cancer.